TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8053664
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human nerve growth factor (rhNGF) subcutaneous doses
Study: 8053664
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human nerve growth factor (rhNGF) intravenous doses
Study: 2970218
Drug: High-dose medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose medroxyprogesterone acetate plus mitomycin-C (MMC)
Study: 2970218
Drug: High-dose medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose medroxyprogesterone acetate plus vindesine
Study: 31674161
Drug: Neurofeedback augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurofeedback augmentation group (n = 12)
Study: 31674161
Drug: Medication-only (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-only (treatment as usual [TAU] group, n = 12)
Study: 21218023
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (identical treatment program without insight enhancement)
Study: 19110596
Drug: Granulocytic CSF
Normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granulocytic CSF (neupogen) added to chemotherapy
Study: 19110596
Drug: Chemotherapy (adriablastine+taxotere)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (adriablastine+taxotere) without neupogen
Study: 10739360
Drug: Granisetron (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (2 mg/m2) plus dexamethasone (8 mg/m2)
Study: 10739360
Drug: Ondansetron (5.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (5.3 mg/m2) plus dexamethasone (8 mg/m2)
Study: 10739360
Drug: Tropisetron (3.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron (3.3 mg/m2) plus dexamethasone (8 mg/m2)
Study: 10739360
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with IFO
Study: 10739360
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with CDP/ADM
Study: 8959118
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 1 mg day‐1
Study: 8959118
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) 2 mg day‐1
Study: 1530423
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg isosorbide dinitrate once daily
Study: 1530423
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg isosorbide dinitrate three times daily
Study: 6199177
Drug: Combined use
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined use of mexiletine (200 mg three times daily) and propranolol (20 mg three times daily)
Study: 25378931
Drug: High-H2 water
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-H2 water containing 7 ppm H2 (3.5 mg H2 in 500 mL water)
Study: 21819594
Drug: McKenzie treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: McKenzie treatment program
Study: 21819594
Drug: Back School
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Back School treatment program
Study: 11593067
Drug: Diuretics, digoxin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics, digoxin, angiotensin‐converting enzyme inhibitors, beta‐blockers; specific dosages and durations not available.
Study: 8988914
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A dosing
Study: 30709402
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention designed to reduce exposure to second-hand smoke; details on dosage and duration not specified.
Study: 26405990
Drug: Conventional clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional clinical therapy
Study: 23280141
Drug: Acetazolamide (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (125 mg Bid, n=11)
Study: 15283899
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of finasteride daily for 7 years
Study: 9470059
Drug: Captopril (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (75 mg/day) plus losartan (25 mg/day)
Study: 9470059
Drug: Captopril (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (75 mg/day) plus placebo
Study: 2451383
Drug: PUVA treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUVA treatment, 10 systemic treatments
Study: 2451383
Drug: Mechlorethamine (HN2)
DrugBank: Mechlorethamine (DB00888)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechlorethamine (HN2) treatment, 3 weeks duration
Study: 29742924
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Policosanol (POL) and Pentoxifylline (PTX)
Study: 28904061
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (GTE) supplementation (4 decaffeinated GTE capsules containing 1,315 mg total catechins, including 843 mg EGCG for 12 months)
Study: 21159789
Drug: 3.4 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.4 g/d EPA+DHA
Study: 21159789
Drug: 0.85 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.85 g/d EPA+DHA
Study: 9421348
Drug: Milnacipran (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milnacipran (200 mg daily for weeks 2-10, flexible dosing 100-200 mg daily for weeks 11-26)
Study: 9421348
Drug: Clomipramine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (150 mg daily for weeks 2-10, flexible dosing 75-150 mg daily for weeks 11-26)
Study: 8098588
Drug: Vecuronium (0.12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (0.12 mg.kg‐1; ED95 x 2)
Study: 8098588
Drug: Atracurium (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (0.4 mg.kg‐1; ED95 x 2)
Study: 3534583
Drug: RT +
Normalized name: CVS Yogurt + Fiber Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT + TAM (10 mg three times daily for 1 yr)
Study: 19929191
Drug: Erythropoietin (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (EPO) 30,000 U intravenous every 48 hours for 3 doses
Study: 1632006
Drug: District psychiatric
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: District psychiatric treatment after discharge
Study: 6716990
Drug: NU-CHIPS administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: NU-CHIPS administered in noise at S/N = -4
Study: 6716990
Drug: NU-CHIPS administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: NU-CHIPS administered in noise at S/N = 0
Study: 6716990
Drug: NU-CHIPS administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: NU-CHIPS administered in noise at S/N = +2
Study: 28930912
Drug: ivabradine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivabradine (5 mg twice daily) for 96 hours
Study: 6411497
Drug: Pentoxifylline (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (1200 mg/day)
Study: 7583868
Drug: Oxatomide (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxatomide (60 mg daily for 7 days)
Study: 2153735
Drug: Acyclovir 400
Normalized name: acyclovir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 400 mg five times daily for 5 days
Study: 28609349
Drug: IDEAL IMPLANT
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IDEAL IMPLANT Core Study
Study: 28609349
Drug: Other breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other breast implant trials (MemoryShape, Allergan 410, Sientra Core Studies)
Study: 16385106
Drug: New therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: New therapies in clinical trials
Study: 16385106
Drug: Mechanism-based approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanism-based approach to treatment
Study: 16385106
Drug: Study designs
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study designs and potential solutions
Study: 12236487
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid at doses of 600, 1200, and 1800 mg/day
Study: 12236487
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of ursodeoxycholic acid (not specified)
Study: 8582916
Drug: Topical RGD
Normalized name: Delta24-RGD
DrugBank: Tasadenoturev (DB17178)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical RGD peptide matrix
Study: 8582916
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment with silver sulfadiazine
Study: 2669473
Drug: Prazosin GITS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin GITS (Minipress XL) 10 mg
Study: 2669473
Drug: Prazosin GITS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin GITS (Minipress XL) 20 mg
Study: 2669473
Drug: Prazosin GITS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin GITS (Minipress XL) (10, 20 mg)
Study: 28625383
Drug: Single antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single antiplatelet therapy or no therapy (control)
Study: 17296463
Drug: Ofloxacin ER
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin ER 400 mg QD
Study: 17296463
Drug: Ofloxacin IR
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin IR 200 mg BID
Study: 14625264
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g of alcohol per day
Study: 14625264
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g of alcohol per day
Study: 7818063
Drug: Vecuronium administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium administered by the Springfusor infusion device
Study: 7818063
Drug: Vecuronium by
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium by intermittent bolus injection
Study: 3247518
Drug: Ketotifen (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (two 1‐mg capsules)
Study: 31288778
Drug: Pelvic plexus
Normalized name: Bos taurus solar plexus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic plexus block (PPB) with 5 ml of 1% lidocaine
Study: 31288778
Drug: Conventional periprostatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional periprostatic nerve block (PNB) with 5 ml of 1% lidocaine
Study: 31288778
Drug: Prostate capsule
Normalized name: Sus scrofa prostate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostate capsule local anesthesia with 22 ml of 1% lidocaine (Control group)
Study: 26425886
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (E2) for 1 week
Study: 22044856
Drug: Therapeutic drug
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic drug monitoring (TDM) with PI dose escalation
Study: 15306005
Drug: Fast rectal
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast rectal distension at 100 mL min(‐1)
Study: 15306005
Drug: Slow rectal
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow rectal distension at 10 mL min(‐1)
Study: 11296014
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of brimonidine and timolol
Study: 9032494
Drug: Ketotifen, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen, 2 mg.day‐1
Study: 30354703
Drug: Morning dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning dosing of antihypertensive agents
Study: 30354703
Drug: Evening dosing
Normalized name: Evening Dosing 24 HR Jornay 60 MG Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening dosing of antihypertensive agents
Study: 29944706
Drug: Daily self-weighing
Normalized name: DAILY SELF DISCOVERY SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily self-weighing (DSW)
Study: 8810613
Drug: Manual titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual titration
Study: 18650127
Drug: Automatic titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automatic titration
Study: 15588342
Drug: Indinavir and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir and efavirenz combination therapy
Study: 7888703
Drug: Anal submucosal
Normalized name: Mephitis mephitis anal gland fluid preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anal submucosal injection of methotrexate (MXT) 50 mg
Study: 7888703
Drug: Parenteral injection
Normalized name: WATER 1 mL in 1 mL PARENTERAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral injection of methotrexate (MXT) 50 mg
Study: 3209832
Drug: Intracervical PGE2
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intracervical PGE2 gel application
Study: 27702806
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel application
Study: 18326610
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg Fe + 400 microg folate
Study: 9245683
Drug: Cognitive-behavioral smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral smoking cessation treatment plus vigorous exercise
Study: 12649057
Drug: Cognitive-behavioral smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral smoking cessation treatment plus contact control
Study: 8438811
Drug: ADTP vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADTP vaccine
Study: 8438811
Drug: WDTP vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WDTP vaccine
Study: 2574594
Drug: Terfenadine 120
Normalized name: terfenadine 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine 120 mg twice daily
Study: 24355952
Drug: Probiotic ice-cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic ice-cream (100 ml)
Study: 24355952
Drug: Probiotic curd
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic curd (100 ml)
Study: 24355952
Drug: Plain ice-cream
Normalized name: clioquinol Topical Cream [Iodo Plain]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain ice-cream (100 ml)
Study: 24355952
Drug: Plain curd
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain curd (100 ml)
Study: 22164745
Drug: ISMN 40
Normalized name: ISMN
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ISMN 40 mg
Study: 22164745
Drug: ISMN ‐
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISMN ‐ SR 60 mg
Study: 22164745
Drug: Placebo Vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Vitamin C 100 mg
Study: 22164745
Drug: ISMN groups
Normalized name: ISMN
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ISMN groups (both ISMN 40 mg and ISMN ‐ SR 60 mg)
Study: 15656713
Drug: Krill oil
Normalized name: Krill oil
DrugBank: Krill oil (DB16615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krill oil 1-3 g per day (BMI-dependent)
Study: 15656713
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (3 g daily containing 180 mg EPA and 120 mg DHA)
Study: 9140154
Drug: Omeprazole (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (80 mg + mg/h) continuous infusion for 72 hours
Study: 22653986
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin (0.3 mg) in exercise group (EX)
Study: 22653986
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin (0.3 mg) in control group (CON)
Study: 22653986
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin (0.3 mg) in both groups
Study: 7854929
Drug: IMED 980
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMED 980 infusion pump
Study: 7854929
Drug: Gemini infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gemini infusion pump
Study: 1008239
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg of 1,8% dextran in lactated Ringer's solution
Study: 1008239
Drug: Enflurane anaesthesia
Normalized name: Enflurane
DrugBank: Enflurane (DB00228)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enflurane anaesthesia with preanaesthetic volume administration
Study: 28247675
Drug: Vitaprost forte
Normalized name: Erythroped Forte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitaprost forte (rectal suppositories) and Vitaprost tablets
Study: 28247675
Drug: Standard anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anti-inflammatory therapy
Study: 28247675
Drug: Vitaprost treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitaprost treatment
Study: 23188563
Drug: Minilaparoscopic (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minilaparoscopic (ML) Cholecystectomy
Study: 9116434
Drug: NaHCO3 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NaHCO3 therapy (2 mmol/kg/day for 7 days)
Study: 9116434
Drug: NaCl therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl therapy (2 mmol/kg/day for 7 days)
Study: 7506150
Drug: Paracetamol 500mg
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol 500mg
Study: 2411246
Drug: Zimeldine (individualized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimeldine (individualized doses to achieve plasma concentrations of 50 to 100 ng/mL)
Study: 30236237
Drug: Sugammadex 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 4 mg kg-1
Study: 30236237
Drug: Sugammadex 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 16 mg kg-1
Study: 26754331
Drug: AndroForte 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AndroForte 5 testosterone cream
Study: 26754331
Drug: Testogel 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testogel 1% testosterone gel
Study: 9796053
Drug: DTPa-HBV/Hib vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPa-HBV/Hib vaccines co-administered with oral polio vaccine
Study: 7637191
Drug: Vecuronium (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (0.03 mg.kg‐1)
Study: 7637191
Drug: Vecuronium (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (0.03 mg.kg‐1) after succinylcholine (1.0 mg.kg‐1)
Study: 7637191
Drug: Succinylcholine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine (1.0 mg.kg‐1) followed by vecuronium (0.03 mg.kg‐1)
Study: 2793383
Drug: Acivicin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acivicin (60 mg/m2/course, administered as a 72‐hr infusion)
Study: 2793383
Drug: Vinblastine (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinblastine (7.5 mg/m2/course, administered as a 120‐hr infusion)
Study: 350473
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg aspirin and 64 mg caffeine (aspirin-caffeine)
Study: 24102344
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy plus iloprost (administered for 10 days every 3 months)
Study: 24102344
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy (Control Group A)
Study: 24102344
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy plus iloprost
Study: 20498326
Drug: RDEA806 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: RDEA806 (400 mg twice a day)
Study: 20498326
Drug: RDEA806 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: RDEA806 (600 mg once a day)
Study: 20498326
Drug: RDEA806 (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: RDEA806 (800 mg once a day)
Study: 20498326
Drug: RDEA806 (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: RDEA806 (1,000 mg once a day)
Study: 16552549
Drug: Hamstring tendon
Normalized name: Bos taurus tendon preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hamstring tendon with titanium metal plate suspension and screw-washer postdistally
Study: 14634404
Drug: Rectal sensation
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal sensation test used during apical biopsy
Study: 14634404
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without rectal sensation test
Study: 10801252
Drug: Lanepitant (20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanepitant (20, 60, 200, or 600 mg initial dose, followed by 10, 30, 100, or 300 mg twice a day)
Study: 10801252
Drug: Naproxen (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (375 mg twice a day)
Study: 22697441
Drug: False safety
Normalized name: ALLERGENIC EXTRACT, FALSE RAGWEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: False safety behavior elimination therapy (F-SET)
Study: 18568502
Drug: Intranasal microemulsion
Normalized name: cyclosporine microemulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal microemulsion treatment
Study: 15821951
Drug: LY544344 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY544344 (80 mg bid for 1 week)
Study: 11830461
Drug: Foscarnet (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foscarnet (60 mg/kg for 2 weeks, then 90 mg/kg for 2 weeks if needed)
Study: 11830461
Drug: Ganciclovir (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganciclovir (5 mg/kg every 12 hours for 2 weeks, then 6 mg/kg once daily for 5 days per week if needed)
Study: 12212053
Drug: Captopril (along
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (along with antibiotics and oxygen) for 14 days